The antiapoptotic function of miR-96 in prostate cancer by inhibition of FOXO1

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Fendler, Annika ^a   Jung, Monika ^a   Stephan, Carsten ^a,b   Erbersdobler, Andreas ^c   Jung, Klaus ^a,b   Yousef, George M ^d,e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Institute for Urologic Research   (Germany)

^c ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3' UNTRANSLATED REGIONS; AGED; APOPTOSIS; BASE PAIRING; BASE SEQUENCE; CELL LINE, TUMOR; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RNA INTERFERENCE;

EID: 84894130549     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080807     Document Type: Article

References (47)

1. Filipowicz W, Bhattacharyya SN, Sonenberg N (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9: 102-114. PubMed: 18197166.
2. Esquela-Kerscher A, Slack FJ (2006) Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269. doi:10.1038/nrc1840. PubMed: 16557279.
3. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300. doi:10.3322/caac.20073. PubMed: 20610543.
4. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM et al. (2008) Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68: 6162-6170. doi:10.1158/0008-5472.CAN-08-0144. PubMed: 18676839.
5. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL et al. (2007) MicroRNA expression profiling in prostate cancer. Cancer Res 67: 6130-6135. doi:10.1158/0008-5472.CAN-07-0533. PubMed: 17616669. (Pubitemid 47037493)
6. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C et al. (2010) Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126: 1166-1176. PubMed: 19676045.
7. Spahn M, Kneitz S, Scholz CJ, Stenger N, Rüdiger T et al. (2010) Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 127: 394-403. PubMed: 19585579.
8. Tong AW, Fulgham P, Jay C, Chen P, Khalil I et al. (2009) MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 16: 206-216. PubMed: 18949015.
9. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103: 2257-2261. doi:10.1073/pnas.0510565103. PubMed: 16461460. (Pubitemid 43271657)
10. Lin SL, Chiang A, Chang D, Ying SY (2008) Loss of mir-146a function in hormone-refractory prostate cancer. RNA 14: 417-424. doi:10.1261/rna.874808. PubMed: 18174313. (Pubitemid 351397806)
11. Machida S, Spangenburg EE, Booth FW (2003) Forkhead transcription factor FoxO1 transduces insulin-like growth factor's signal to p27Kip1 in primary skeletal muscle satellite cells. J Cell Physiol 196: 523-531. doi:10.1002/jcp.10339. PubMed: 12891709. (Pubitemid 36927747)
12. Kim SJ, Winter K, Nian C, Tsuneoka M, Koda Y et al. (2005) Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression. J Biol Chem 280: 22297-22307. doi:10.1074/jbc.M500540200. PubMed: 15817464. (Pubitemid 40827886)
13. Rena G, Guo S, Cichy SC, Unterman TG, Cohen P (1999) Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem 274: 17179-17183. doi:10.1074/jbc.274.24.17179. PubMed: 10358075.
14. Guttilla IK, White BA (2009) Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem 284: 23204-23216. doi:10.1074/jbc.M109.031427. PubMed: 19574223.
15. Myatt SS, Wang J, Monteiro LJ, Christian M, Ho KK et al. (2010) Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res 70: 367-377. doi:10.1158/0008-5472.CAN- 09-1891. PubMed: 20028871.
16. Xie L, Ushmorov A, Leithäuser F, Guan H, Steidl C et al. (2012) FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood 119: 3503-3511. doi:10.1182/blood-2011-09-381905. PubMed: 22343918.
17. van Kuppeveld FJ, Johansson KE, Galama JM, Kissing J, Bölske G et al. (1994) Detection of mycoplasma contamination in cell cultures by a mycoplasma group-specific PCR. Appl Environ Microbiol 60: 149-152. PubMed: 7509584. (Pubitemid 24019931)
18. Gunia S, May M, Koch S, Dietel M, Erbersdobler A (2010) MUC1 expression in incidental prostate cancer predicts staging and grading on the subsequent radical prostatectomy. Pathol Oncol Res 16: 371-375. doi:10.1007/s12253-009- 9231-4. PubMed: 19943130.
19. Ohl F, Jung M, Xu C, Stephan C, Rabien A et al. (2005) Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization? J Mol Med (Berl) 83: 1014-1024. doi:10.1007/s00109-005-0703-z. PubMed: 16211407. (Pubitemid 41745760)
20. Gebäck T, Schulz MM, Koumoutsakos P, Detmar M (2009) TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. BioTechniques 46: 265-274. PubMed: 19450233.
21. Rabien A, Fritzsche FR, Jung M, Tölle A, Diamandis EP et al. (2010) KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy. Int J Cancer 127: 2386-2394. doi:10.1002/ijc.25435. PubMed: 20473923.
22. Li T, Li D, Sha J, Sun P, Huang Y (2009) MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun 383: 280-285. doi:10.1016/j.bbrc.2009.03.077. PubMed: 19302977.
23. Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R et al. (2008) Widespread changes in protein synthesis induced by microRNAs. Nature 455: 58-63. doi:10.1038/nature07228. PubMed: 18668040.
24. Xu S, Witmer PD, Lumayag S, Kovacs B, Valle D (2007) MicroRNA (miRNA) transcriptome of mouse retina and identification of a sensory organ-specific miRNA cluster. J Biol Chem 282: 25053-25066. doi:10.1074/jbc.M700501200. PubMed: 17597072. (Pubitemid 47347506)
25. Loscher CJ, Hokamp K, Kenna PF, Ivens AC, Humphries P et al. (2007) Altered retinal microRNA expression profile in a mouse model of retinitis pigmentosa. Genome Biol 8: R248. doi:10.1186/gb-2007-8-11-r248. PubMed: 18034880.
26. Sacheli R, Nguyen L, Borgs L, Vandenbosch R, Bodson M et al. (2009) Expression patterns of miR-96, miR-182 and miR-183 in the development inner ear. Gene Expr Patterns 9: 364-370. doi:10.1016/j.gep.2009.01.003. PubMed: 19602392.
27. Gokhale A, Kunder R, Goel A, Sarin R, Moiyadi A et al. (2010) Distinctive microRNA signature of medulloblastomas associated with the WNT signaling pathway. J Cancer Res Ther 6: 521-529. doi:10.4103/0973-1482.77072. PubMed: 21358093.
28. Lin H, Dai T, Xiong H, Zhao X, Chen X et al. (2010) Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a. PLOS ONE 5: e15797. doi:10.1371/journal.pone. 0015797. PubMed: 21203424.
29. Navon R, Wang H, Steinfeld I, Tsalenko A, Ben-Dor A et al. (2009) Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLOS ONE 4: e8003. doi:10.1371/journal.pone.0008003. PubMed: 19946373.
30. Sarver AL, French AJ, Borralho PM, Thayanithy V, Oberg AL et al. (2009) Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer 9: 401. doi:10.1186/1471-2407-9-401. PubMed: 19922656.
31. Sato F, Hatano E, Kitamura K, Myomoto A, Fujiwara T et al. (2011) MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PLOS ONE 6: e16435. doi:10.1371/journal.pone.0016435. PubMed: 21298008.
32. Mihelich BL, Khramtsova EA, Arva N, Vaishnav A, Johnson DN et al. (2011) miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells. J Biol Chem 286: 44503-44511. doi:10.1074/jbc.M111.262915. PubMed: 22045813.
33. Wang Y, Luo H, Li Y, Chen T, Wu S et al. (2012) hsa-miR-96 upregulates MAP4K1 and IRS1 and may function as a promising diagnostic marker in human bladder urothelial carcinomas. Mol Med Report 5: 260-265
34. Yu S, Lu Z, Liu C, Meng Y, Ma Y et al. (2010) miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res 70: 6015-6025. doi:10.1158/0008-5472.CAN-09-4531. PubMed: 20610624.
35. Han S, Wei W (2011) Camptothecin induces apoptosis of human retinoblastoma cells via activation of FOXO1. Curr Eye Res 36: 71-77. doi:10.3109/02713683.2010.510943. PubMed: 21174601.
36. Huang H, Regan KM, Lou Z, Chen J, Tindall DJ (2006) CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science 314: 294-297. doi:10.1126/science.1130512. PubMed: 17038621. (Pubitemid 44571973)
37. Zeng FY, Cui J, Liu L, Chen T (2009) PAX3-FKHR sensitizes human alveolar rhabdomyosarcoma cells to camptothecin-mediated growth inhibition and apoptosis. Cancer Lett 284: 157-164. doi:10.1016/j.canlet.2009.04.016. PubMed: 19442434.
38. Liu P, Kao TP, Huang H (2008) CDK1 promotes cell proliferation and survival via phosphorylation and inhibition of FOXO1 transcription factor. Oncogene 27: 4733-4744. doi:10.1038/onc.2008.104. PubMed: 18408765.
39. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D et al. (2004) Mammalian SIRT1 represses forkhead transcription factors. Cell 116: 551-563. doi:10.1016/S0092-8674(04)00126-6. PubMed: 14980222. (Pubitemid 38264432)
40. Matsuzaki H, Daitoku H, Hatta M, Tanaka K, Fukamizu A (2003) Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc Natl Acad Sci U S A 100: 11285-11290. doi:10.1073/pnas. 1934283100. PubMed: 13679577. (Pubitemid 37205927)
41. Kops GJ, Medema RH, Glassford J, Essers MA, Dijkers PF et al. (2002) Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol 22: 2025-2036. doi:10.1128/MCB.22.7.2025- 2036.2002. PubMed: 11884591. (Pubitemid 34224611)
42. Modur V, Nagarajan R, Evers BM, Milbrandt J (2002) FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 277: 47928-47937. doi:10.1074/jbc.M207509200. PubMed: 12351634. (Pubitemid 36159321)
43. Morgan TM, Koreckij TD, Corey E (2009) Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 9: 237-249. doi:10.2174/156800909787580999. PubMed: 19275762.
44. Dong XY, Chen C, Sun X, Guo P, Vessella RL et al. (2006) FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res 66: 6998-7006. doi:10.1158/0008-5472. CAN-06-0411. PubMed: 16849544. (Pubitemid 44197675)
45. Jalvy-Delvaille S, Maurel M, Majo V, Pierre N, Chabas S et al. (2012) Molecular basis of differential target regulation by miR-96 and miR-182: the Glypican-3 as a model. Nucleic Acids Res 40: 1356-1365. doi:10.1093/nar/gkr843. PubMed: 22009679.
46. Li R, Erdamar S, Dai H, Wheeler TM, Frolov A et al. (2007) Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer. Hum Pathol 38: 1501-1507. doi:10.1016/j.humpath.2007.02.016. PubMed: 17597184. (Pubitemid 47418961)
47. Lein M, Stibane I, Mansour R, Hege C, Roigas J et al. (2006) Complications, urinary continence, and oncologic outcome of 1000 laparoscopic transperitoneal radical prostatectomies-experience at the Charite Hospital Berlin, Campus Mitte. European Urology 50: 1278-1282; discussion: 1283-1274.